BeiGene | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Beigene Study ID

BGB-290-103

ClinicalTrials.gov ID

NCT03150810

EudraCT Number

2017-001553-14

Study Overview

Sex: All

Age: 18 Years / 99 Years

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary